Topic: Nxclinical
Top 25 Biotech CEOs of 2020 - Soheil Shams
Since the advent of advanced genomics, and the subsequent rise of automation, the data generated in clinical testing and research sees a 100 fold increase each year making the storage, security and management of patient data quite a daunting task for companies to mine the data to find the factors that drive a patient’s disease. That’s where BioDiscovery comes in. Their flagship solution NxClinical, is a unique software tool for integrated analysis of copy number, sequence variants, and allelic changes obtained from multiple technologies. The solution combines NGS and Array data through advanced mining and filtering techniques which allows the data to be clear and digestible for clinicians.
BioDiscovery - A Top 10 Genetic Diagnostic Company
Since the advent of advanced genomics, and the subsequent rise of automation, the data generated in clinical testing and research sees a 100 fold increase each year making the storage, security and management of patient data quite a daunting task for companies to mine the data to find the factors that drive a patient’s disease. That’s where BioDiscovery comes in. Their flagship solution NxClinical, is a unique software tool for integrated analysis of copy number, sequence variants, and allelic changes obtained from multiple technologies. The solution combines NGS and Array data through advanced mining and filtering techniques which allows the data to be clear and digestible for clinicians.
BioDiscovery Designates Children’s Hospital of Los Angeles as a Center of Excellence for Clinical Genomics
Children’s Hospital of Los Angeles (CHLA), an award-winning hospital with comprehensive medical care services and programs for children, has signed on as a BioDiscovery Center of Excellence for Clinical Genomics to serve as a reference site for others seeking information and training on BioDiscovery’s NxClinical software.
BioDiscovery launches NxClinical 4.1, a comprehensive system allowing interpretation of variants of any size from SNVs to large CNVs
NxClinical 4.1 is a unique software solution for integration of copy number, sequence variants, and allelic changes obtained from microarray and NGS technologies. NxClinical 4.1 allows combined analysis and interpretation of all genomic variants on a single, platform agnostic system.
BioDiscovery Inc. Forms Partnership with Be Creative Lab (Beijing) Co. Ltd. For Distribution of NxClinical Software
BioDiscovery announced today an agreement with Be Creative Lab in Beijing, China to be the exclusive reseller and distributor of BioDiscovery products in China.
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay.
GENALICE and BioDiscovery Partner to Empower Rapid NGS Data Interpretation
GENALICE and BioDiscovery announce a co-marketing partnership to offer their products together as a turn-key end-to-end solution for the use of next-generation sequencing (NGS) data to interpret genomes.
BioDiscovery to announce NxClinical 3.0, a new software to unite data from arrays and NGS, at ASHG 2016
NxClinical 3.0 will be launched during the ASHG 2016 Meeting, October 18-21 in Vancouver, BC, Canada
Ambry Genetics Selects BioDiscovery’s NxClinical Software for Analysis, Management, and Reporting of Copy Number Events in its Clinical Genomics Workflow
Ambry Genetics selects BioDiscovery’s NxClinical software for analysis, management, and reporting of copy number events in its clinical genomics workflow.
Illumina Selects BioDiscovery’s NxClinical Software for Data Visualization, Management and Interpretation for its CytoSeq™ assay, an NGS-based Solution for Detection of CNVs, AOH, and SNVs
Illumina Selects BioDiscovery’s NxClinical Software for Data Visualization, Management and Interpretation for its CytoSeq ™ assay, an NGS-based Solution for Detection of CNVs, AOH, and SNVs
